Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Clinical trial NCT05374603 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05374603
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-15
- Primary completion
- 2027-01-18
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.